retatrutide trial weight loss Retatrutide, a new drug not available on the market yet, is showing promising results in trials. @DrLaPook explains it’s doing much more than what current medications can Retatrutide for Weight Loss: 2026

This commentary summarizes evidence demonstrating beneficial effects of GLP-1 medicines on conditions other than T2D or obesity, including cardiovascular disease (CVD), CKD, MASLD, osteoarthritis (OA), obstructive sleep apnea (OSA), and peripheral artery disease (PAD) (Figure 1A)

It can also produce dizziness, headache, and nausea, the latter impacting roughly 30% of people

Inclusion criteria: Studies on GLP-1 and inflammation Arthritis-related experimental models Publications from 20052025 Exclusion criteria: Non-peer-reviewed articles Studies lacking quantitative data Researchers extracted data about cytokine levels, receptor expression, and cartilage outcomes

Semaglutide could be a significant tool in the weight loss battle for some, however popular media reporting of the skinny jab may raise unrealistic expectations of easy weight loss within the general public

Hims says its providers will now be able to offer GLP-1 microdosing treatment plans, which are presumably at a significantly different dose than those manufactured by Novo, to treat a broader range of conditions

Your body had adjusted to the previous dose and now needs to adjust again